HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G focusing on personal care

This article was originally published in The Rose Sheet

Executive Summary

During annual meeting with investors, Procter & Gamble CEO A.G. Lafley discussed firm's long-term growth plan. "The company we are creating is going to be primarily a household cleaning and personal-care products company, and the reason we're heading in that direction is because our business is driven by consumers in the end and by consumer demographics and by what they're buying and using," Lafley said, explaining company's rationale in divesting Folgers coffee to J.M. Smucker, which also now owns former P&G brands Jif peanut butter and Crisco. Lafley noted that 75% to 80% of U.S. consumers say they will continue to spend at current levels in household and personal care, despite economic downturn. Personal-care-oriented P&G purchased professional hair-care brand Nioxin in September. Also in September P&G shared its strategy for reining in costs (1"The Rose Sheet" Sept. 29, 2008, p. 3)

You may also be interested in...



P&G Outlines Plan For Offsetting Rising Costs Without Sticking It To Consumer

Procter & Gamble is streamlining production, consolidating staff and using innovative product development methods to offset the rising expense of raw materials, manufacturing and shipping without pricing products at levels that may alienate consumers

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel